Clearside Biomedical (NASDAQ:CLSD) Receives “Buy” Rating from Needham & Company LLC
Needham & Company LLC restated their buy rating on shares of Clearside Biomedical (NASDAQ:CLSD – Free Report) in a research note published on Tuesday,Benzinga reports. The brokerage currently has a $4.00 price objective on the stock. Several other equities research analysts have also recently weighed in on CLSD. HC Wainwright reissued a “buy” rating and […]
Needham & Company LLC restated their buy rating on shares of Clearside Biomedical (NASDAQ:CLSD – Free Report) in a research note published on Tuesday,Benzinga reports. The brokerage currently has a $4.00 price objective on the stock. Several other equities research analysts have also recently weighed in on CLSD. HC Wainwright reissued a “buy” rating and […]
